- Home
- BGLC vs APVO Comparison
BGLC vs APVO Comparison
Compare BGLC & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- APVO
- Stock Information
- Founded
- BGLC 2017
- APVO 2016
- Country
- BGLC Malaysia
- APVO United States
- Employees
- BGLC N/A
- APVO N/A
- Industry
- BGLC Medical Specialities
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- APVO Health Care
- Exchange
- BGLC Nasdaq
- APVO Nasdaq
- Market Cap
- BGLC 5.8M
- APVO 5.4M
- IPO Year
- BGLC N/A
- APVO N/A
- Fundamental
- Price
- BGLC $0.29
- APVO $1.99
- Analyst Decision
- BGLC
- APVO Strong Buy
- Analyst Count
- BGLC 0
- APVO 1
- Target Price
- BGLC N/A
- APVO $296.00
- AVG Volume (30 Days)
- BGLC 1.4M
- APVO 5.2M
- Earning Date
- BGLC 05-14-2025
- APVO 05-07-2025
- Dividend Yield
- BGLC N/A
- APVO N/A
- EPS Growth
- BGLC N/A
- APVO N/A
- EPS
- BGLC N/A
- APVO N/A
- Revenue
- BGLC $9,259,858.00
- APVO N/A
- Revenue This Year
- BGLC N/A
- APVO N/A
- Revenue Next Year
- BGLC N/A
- APVO N/A
- P/E Ratio
- BGLC N/A
- APVO N/A
- Revenue Growth
- BGLC N/A
- APVO N/A
- 52 Week Low
- BGLC $0.21
- APVO $0.94
- 52 Week High
- BGLC $1.00
- APVO $180.19
- Technical
- Relative Strength Index (RSI)
- BGLC 45.41
- APVO 44.91
- Support Level
- BGLC $0.23
- APVO $0.94
- Resistance Level
- BGLC $0.29
- APVO $3.61
- Average True Range (ATR)
- BGLC 0.03
- APVO 0.53
- MACD
- BGLC -0.00
- APVO -0.00
- Stochastic Oscillator
- BGLC 47.67
- APVO 39.28
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.